Ex parte VERMA et al. - Page 8



                Appeal No. 1999-1221                                                                          
                Application No. 08/342-242                                                                    

                expression of jun.  See Figure 2.  We note that TPA is one of the compounds                   
                tested in the specification for its effect on fos expression.  See Example 2.  Kelly          
                appears to disclose a method comprising exposing cells that express myc to                    
                compounds, including PDGF, and monitoring changes in the expression of myc.                   
                See Figure 4.  We note that PDGF is one of the compounds tested in the                        
                specification for its effect on fos expression.  See Example 2.  The examiner                 
                should consider whether Lamph or Kelly, or other prior art disclosures, anticipate            
                the instantly claimed method.                                                                 





























                                                      8                                                       



Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next 

Last modified: November 3, 2007